These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 30277860)

  • 1. Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database.
    Carreira PE; Carmona L; Joven BE; Loza E; Andreu JL; Riemekasten G; Vettori S; Balbir-Gurman A; Airò P; Walker UA; Damjanov N; Matucci-Cerinic M; Ananieva LP; Rednic S; Czirják L; Distler O; Farge D; Hesselstrand R; Corrado A; Caramaschi P; Tikly M; Allanore Y;
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):68-75. PubMed ID: 30277860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
    Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
    Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database.
    Carreira PE; Carmona L; Joven BE; Loza E; Andréu JL; Riemekasten G; Vettori S; Balbir-Gurman A; Airò P; Walker U; Damjanov N; Matucci-Cerinic M; Ananieva LP; Rednic S; Czirják L; Distler O; Farge D; Hesselstrand R; Corrado A; Caramaschi P; Tikly M; Allanore Y
    Scand J Rheumatol; 2019 Jan; 48(1):42-51. PubMed ID: 30039730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to diagnosis in systemic sclerosis: is sex a factor?
    Hudson M; Thombs B; Baron M;
    Arthritis Rheum; 2009 Feb; 61(2):274-8. PubMed ID: 19177534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry.
    Delisle VC; Hudson M; Baron M; Thombs BD; And The Canadian Scleroderma Research Group A
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-10-4. PubMed ID: 24144459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
    Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
    Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.
    Meier FM; Frommer KW; Dinser R; Walker UA; Czirjak L; Denton CP; Allanore Y; Distler O; Riemekasten G; Valentini G; Müller-Ladner U;
    Ann Rheum Dis; 2012 Aug; 71(8):1355-60. PubMed ID: 22615460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.
    Foocharoen C; Watcharenwong P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
    Int J Rheum Dis; 2017 Oct; 20(10):1572-1581. PubMed ID: 28296274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database.
    Schneeberger D; Tyndall A; Kay J; Søndergaard KH; Carreira PE; Morgiel E; Deuschle K; Derk CT; Widuchowska M; Walker UA
    Rheumatology (Oxford); 2013 Mar; 52(3):560-7. PubMed ID: 23221323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma.
    Shah AA; Montagne J; Oh SY; Wigley FM; Casciola-Rosen L
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S123-6. PubMed ID: 26242276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of 405 Japanese patients with systemic sclerosis.
    Hashimoto A; Endo H; Kondo H; Hirohata S
    Mod Rheumatol; 2012 Apr; 22(2):272-9. PubMed ID: 21874591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased messenger RNA levels of the mesenchymal cadherin-11 in the peripheral blood of systemic sclerosis patients correlate with diffuse skin involvement.
    Christopoulos PF; Bournia VK; Panopoulos S; Vaiopoulos A; Koutsilieris M; Sfikakis PP
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S36-9. PubMed ID: 26121083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of organ involvement in systemic sclerosis by serum biomarkers and peripheral endothelial function.
    Kawashiri SY; Nishino A; Igawa T; Takatani A; Shimizu T; Umeda M; Fukui S; Okada A; Suzuki T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakashima M; Mizokami A; Matsuoka N; Migita K; Ogawa F; Ikeda S; Maemura K; Nakamura H; Origuchi T; Maeda T; Kawakami A
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):102-108. PubMed ID: 29652651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.
    van den Hoogen F; Khanna D; Fransen J; Johnson SR; Baron M; Tyndall A; Matucci-Cerinic M; Naden RP; Medsger TA; Carreira PE; Riemekasten G; Clements PJ; Denton CP; Distler O; Allanore Y; Furst DE; Gabrielli A; Mayes MD; van Laar JM; Seibold JR; Czirjak L; Steen VD; Inanc M; Kowal-Bielecka O; Müller-Ladner U; Valentini G; Veale DJ; Vonk MC; Walker UA; Chung L; Collier DH; Ellen Csuka M; Fessler BJ; Guiducci S; Herrick A; Hsu VM; Jimenez S; Kahaleh B; Merkel PA; Sierakowski S; Silver RM; Simms RW; Varga J; Pope JE
    Ann Rheum Dis; 2013 Nov; 72(11):1747-55. PubMed ID: 24092682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis.
    Sobanski V; Giovannelli J; Allanore Y; Riemekasten G; Airò P; Vettori S; Cozzi F; Distler O; Matucci-Cerinic M; Denton C; Launay D; Hachulla E;
    Arthritis Rheumatol; 2019 Sep; 71(9):1553-1570. PubMed ID: 30969034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Classification criteria of scleroderma].
    Cabane J;
    Presse Med; 2006 Dec; 35(12 Pt 2):1916-22. PubMed ID: 17159717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database.
    Walker UA; Tyndall A; Czirják L; Denton CP; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 Jun; 68(6):856-62. PubMed ID: 18625615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study.
    Heijnen IA; Foocharoen C; Bannert B; Carreira PE; Caporali R; Smith V; Kumánovics G; Becker MO; Vanthuyne M; Simsek I; Bocelli-Tyndall C; Walker UA
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):96-102. PubMed ID: 23101460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.